Trade Seattle Genetics, Inc. - SGEN CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
- Ownership
Trading Conditions
| Spread | 0.17 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
Seagen Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 212.07 |
| Open* | 212.6 |
| 1-Year Change* | 54.45% |
| Day's Range* | 212.03 - 213.17 |
| 52 wk Range | 116.08-210.50 |
| Average Volume (10 days) | 1.70M |
| Average Volume (3 months) | 24.05M |
| Market Cap | 38.46B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 187.70M |
| Revenue | 2.16B |
| EPS | -3.89 |
| Dividend (Yield %) | N/A |
| Beta | 0.48 |
| Next Earnings Date | Oct 25, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Sep 29, 2023 | 212.14 | 0.27 | 0.13% | 211.87 | 213.41 | 211.70 |
| Sep 28, 2023 | 212.07 | -0.35 | -0.16% | 212.42 | 212.75 | 211.54 |
| Sep 27, 2023 | 212.31 | -2.12 | -0.99% | 214.43 | 214.76 | 212.13 |
| Sep 26, 2023 | 215.91 | 0.76 | 0.35% | 215.15 | 216.97 | 215.13 |
| Sep 25, 2023 | 215.40 | 2.35 | 1.10% | 213.05 | 215.63 | 213.05 |
| Sep 22, 2023 | 213.56 | -0.19 | -0.09% | 213.75 | 213.93 | 212.95 |
| Sep 21, 2023 | 206.31 | 0.57 | 0.28% | 205.74 | 207.45 | 205.29 |
| Sep 20, 2023 | 206.96 | -0.26 | -0.13% | 207.22 | 208.18 | 206.42 |
| Sep 19, 2023 | 208.05 | 1.49 | 0.72% | 206.56 | 208.58 | 206.19 |
| Sep 18, 2023 | 207.12 | 0.26 | 0.13% | 206.86 | 208.09 | 206.70 |
| Sep 15, 2023 | 208.24 | 2.03 | 0.98% | 206.21 | 208.34 | 204.95 |
| Sep 14, 2023 | 206.35 | 0.45 | 0.22% | 205.90 | 207.06 | 205.87 |
| Sep 13, 2023 | 205.82 | 0.87 | 0.42% | 204.95 | 207.42 | 204.95 |
| Sep 12, 2023 | 207.30 | 0.96 | 0.47% | 206.34 | 207.87 | 206.23 |
| Sep 11, 2023 | 208.01 | 3.86 | 1.89% | 204.15 | 208.37 | 203.10 |
| Sep 8, 2023 | 204.36 | 0.06 | 0.03% | 204.30 | 205.23 | 203.46 |
| Sep 7, 2023 | 204.78 | -0.47 | -0.23% | 205.25 | 206.15 | 204.67 |
| Sep 6, 2023 | 205.91 | -0.82 | -0.40% | 206.73 | 207.25 | 205.48 |
| Sep 5, 2023 | 207.04 | -0.69 | -0.33% | 207.73 | 208.03 | 206.81 |
| Sep 1, 2023 | 207.76 | -2.17 | -1.03% | 209.93 | 210.32 | 207.39 |
Seattle Genetics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, October 25, 2023 | ||
| Time (UTC) 10:59 | Country US
| Event Q3 2023 Seagen Inc Earnings Release Q3 2023 Seagen Inc Earnings ReleaseForecast -Previous - |
| Tuesday, February 13, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q4 2023 Seagen Inc Earnings Release Q4 2023 Seagen Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 1962.41 | 1574.37 | 2175.54 | 916.713 | 654.7 |
| Revenue | 1962.41 | 1574.37 | 2175.54 | 916.713 | 654.7 |
| Cost of Revenue, Total | 410.058 | 311.565 | 217.72 | 43.952 | 88.293 |
| Gross Profit | 1552.35 | 1262.81 | 1957.82 | 872.761 | 566.407 |
| Total Operating Expense | 2575.38 | 2256.43 | 1578.68 | 1137.26 | 914.698 |
| Selling/General/Admin. Expenses, Total | 820.963 | 716.19 | 533.835 | 373.932 | 252.596 |
| Research & Development | 1344.36 | 1228.67 | 827.129 | 719.374 | 565.309 |
| Operating Income | -612.97 | -682.056 | 596.852 | -220.545 | -259.998 |
| Interest Income (Expense), Net Non-Operating | 10.655 | 6.351 | 18.849 | 61.895 | 13.652 |
| Net Income Before Taxes | -602.315 | -675.705 | 615.701 | -158.65 | -246.346 |
| Net Income After Taxes | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Net Income Before Extra. Items | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Net Income | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Income Available to Common Excl. Extra. Items | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Income Available to Common Incl. Extra. Items | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Diluted Net Income | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Diluted Weighted Average Shares | 184.676 | 182.048 | 182.287 | 165.498 | 157.655 |
| Diluted EPS Excluding Extraordinary Items | -3.30475 | -3.70491 | 3.3665 | -0.95862 | -1.41253 |
| Diluted Normalized EPS | -3.30475 | -3.70491 | 3.3665 | -0.95862 | -1.37749 |
| Total Extraordinary Items | 0 | ||||
| Unusual Expense (Income) | 8.5 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 603.832 | 519.719 | 528.15 | 510.3 | 497.502 |
| Revenue | 603.832 | 519.719 | 528.15 | 510.3 | 497.502 |
| Cost of Revenue, Total | 180.753 | 111.776 | 108.21 | 108.122 | 106.1 |
| Gross Profit | 423.079 | 407.943 | 419.94 | 402.178 | 391.402 |
| Total Operating Expense | 824.553 | 704.232 | 682.154 | 703.105 | 630.613 |
| Selling/General/Admin. Expenses, Total | 236.932 | 206.441 | 216.101 | 210.378 | 220.259 |
| Research & Development | 399.868 | 356.015 | 357.843 | 384.605 | 304.254 |
| Operating Income | -220.721 | -184.513 | -154.004 | -192.805 | -133.111 |
| Interest Income (Expense), Net Non-Operating | 12.084 | 14.4 | 10.176 | 4.278 | -1.609 |
| Net Income Before Taxes | -208.637 | -170.113 | -143.828 | -188.527 | -134.72 |
| Net Income After Taxes | -211.528 | -174.737 | -148.171 | -190.816 | -134.827 |
| Net Income Before Extra. Items | -211.528 | -174.737 | -148.171 | -190.816 | -134.827 |
| Net Income | -211.528 | -174.737 | -148.171 | -190.816 | -134.827 |
| Income Available to Common Excl. Extra. Items | -211.528 | -174.737 | -148.171 | -190.816 | -134.827 |
| Income Available to Common Incl. Extra. Items | -211.528 | -174.737 | -148.171 | -190.816 | -134.827 |
| Diluted Net Income | -211.528 | -174.737 | -148.171 | -190.816 | -134.827 |
| Diluted Weighted Average Shares | 187.559 | 186.889 | 186.107 | 184.792 | 184.145 |
| Diluted EPS Excluding Extraordinary Items | -1.12779 | -0.93498 | -0.79616 | -1.0326 | -0.73218 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -1.10354 | -0.83064 | -0.79616 | -1.0326 | -0.73218 |
| Unusual Expense (Income) | 7 | 30 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 2802.53 | 2869.19 | 3062.38 | 1176.64 | 653.595 |
| Cash and Short Term Investments | 1735.07 | 2160.04 | 2559.42 | 811.055 | 410.672 |
| Cash & Equivalents | 319.94 | 424.834 | 558.424 | 274.562 | 78.186 |
| Short Term Investments | 1415.13 | 1735.2 | 2001 | 536.493 | 332.486 |
| Total Receivables, Net | 501.912 | 389.256 | 324.988 | 236.001 | 146.281 |
| Accounts Receivable - Trade, Net | 501.912 | 389.256 | 324.988 | 236.001 | 146.281 |
| Total Inventory | 427.211 | 200.663 | 116.136 | 85.932 | 53.239 |
| Prepaid Expenses | 134.794 | 119.239 | 61.84 | 43.653 | 43.403 |
| Total Assets | 3674.53 | 3719.6 | 4000.91 | 2205.87 | 1503.33 |
| Property/Plant/Equipment, Total - Net | 294.917 | 267.962 | 258.18 | 220.721 | 103.82 |
| Property/Plant/Equipment, Total - Gross | 551.67 | 480.444 | 434.2 | 365.086 | 225.004 |
| Accumulated Depreciation, Total | -256.753 | -212.482 | -176.02 | -144.365 | -121.184 |
| Intangibles, Net | 237.516 | 260.593 | 283.68 | 300 | 300.04 |
| Long Term Investments | 0 | 100.83 | 57.283 | 49.194 | |
| Other Long Term Assets, Total | 64.895 | 47.184 | 21.161 | 176.55 | 122.009 |
| Total Current Liabilities | 818.404 | 568.854 | 388.138 | 259.357 | 225.072 |
| Accounts Payable | 207.851 | 114.824 | 78.067 | 52.292 | 44.179 |
| Accrued Expenses | 610.553 | 454.03 | 279.941 | 207.065 | 147.293 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 30.13 | 0 | 33.6 | ||
| Total Liabilities | 870.713 | 654.465 | 512.806 | 329.579 | 229.386 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 52.309 | 85.611 | 124.668 | 70.222 | 4.314 |
| Total Equity | 2803.82 | 3065.14 | 3488.1 | 1876.29 | 1273.94 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.187 | 0.183 | 0.181 | 0.172 | 0.16 |
| Additional Paid-In Capital | 4954.47 | 4607.82 | 4356.92 | 3359.12 | 2598.41 |
| Retained Earnings (Accumulated Deficit) | -2154.35 | -1544.04 | -869.568 | -1483.24 | -1324.59 |
| Other Equity, Total | 3.51 | 1.179 | 0.565 | 0.229 | -0.04 |
| Total Liabilities & Shareholders’ Equity | 3674.53 | 3719.6 | 4000.91 | 2205.87 | 1503.33 |
| Total Common Shares Outstanding | 186.559 | 183.381 | 180.902 | 171.994 | 160.262 |
| Goodwill, Net | 274.671 | 274.671 | 274.671 | 274.671 | 274.671 |
| Other Current Assets, Total | 3.546 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 2601.91 | 2802.53 | 2759.62 | 2778.66 | 2771.25 |
| Cash and Short Term Investments | 1490.27 | 1735.07 | 1763.7 | 1850.32 | 1951.09 |
| Cash & Equivalents | 335.847 | 319.94 | 362.601 | 364.874 | 260.996 |
| Short Term Investments | 1154.43 | 1415.13 | 1401.1 | 1485.45 | 1690.1 |
| Total Receivables, Net | 495.777 | 501.912 | 486.755 | 438.041 | 401.009 |
| Accounts Receivable - Trade, Net | 495.777 | 501.912 | 486.755 | 438.041 | 401.009 |
| Total Inventory | 477.694 | 427.211 | 364.97 | 319.354 | 275.747 |
| Prepaid Expenses | 136.979 | 134.794 | 138.423 | 170.938 | 143.406 |
| Total Assets | 3543.3 | 3674.53 | 3619.08 | 3630.34 | 3616.69 |
| Property/Plant/Equipment, Total - Net | 378.957 | 294.917 | 279.61 | 270.843 | 269.316 |
| Goodwill, Net | 274.671 | 274.671 | 274.671 | 274.671 | 274.671 |
| Intangibles, Net | 231.826 | 237.516 | 243.332 | 249.149 | 254.902 |
| Long Term Investments | |||||
| Other Long Term Assets, Total | 55.931 | 64.895 | 61.846 | 57.025 | 46.549 |
| Total Current Liabilities | 713.228 | 818.404 | 725.998 | 608.521 | 531.294 |
| Accounts Payable | 141.475 | 207.851 | 144.499 | 128.872 | 87.228 |
| Accrued Expenses | 571.753 | 610.553 | 581.499 | 479.649 | 444.066 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 820.14 | 870.713 | 797.267 | 697.531 | 618.226 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 106.912 | 52.309 | 71.269 | 89.01 | 86.932 |
| Total Equity | 2723.16 | 2803.82 | 2821.81 | 2932.81 | 2998.47 |
| Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.187 | 0.187 | 0.185 | 0.184 | 0.184 |
| Additional Paid-In Capital | 5048.35 | 4954.47 | 4824.81 | 4747.48 | 4678.39 |
| Retained Earnings (Accumulated Deficit) | -2329.08 | -2154.35 | -2006.18 | -1815.36 | -1680.53 |
| Other Equity, Total | 3.708 | 3.51 | 2.995 | 0.507 | 0.424 |
| Total Liabilities & Shareholders’ Equity | 3543.3 | 3674.53 | 3619.08 | 3630.34 | 3616.69 |
| Total Common Shares Outstanding | 187.289 | 186.559 | 185.234 | 184.369 | 183.892 |
| Other Current Assets, Total | 1.189 | 3.546 | 5.769 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -610.308 | -674.471 | 613.67 | -158.65 | -222.693 |
| Cash From Operating Activities | -453.751 | -499.007 | 856.568 | -163.737 | -203.536 |
| Cash From Operating Activities | 46.727 | 42.854 | 36.045 | 23.774 | 26.032 |
| Non-Cash Items | 236.74 | 196.991 | 149.701 | 83.902 | 70.676 |
| Changes in Working Capital | -150.54 | -88.016 | 42.86 | -112.763 | -53.898 |
| Cash From Investing Activities | 228.237 | 288.884 | -1419.01 | -277.729 | -592.63 |
| Capital Expenditures | -77.34 | -52.33 | -82.409 | -70.753 | -21.219 |
| Other Investing Cash Flow Items, Total | 305.577 | 341.214 | -1336.6 | -206.976 | -571.411 |
| Cash From Financing Activities | 125.36 | 77.779 | 846.108 | 637.842 | 713.407 |
| Issuance (Retirement) of Stock, Net | 125.36 | 77.779 | 846.108 | 637.842 | 713.407 |
| Net Change in Cash | -101.348 | -133.59 | 283.862 | 196.376 | -82.759 |
| Deferred Taxes | 0.553 | 0.548 | -2.053 | 0 | -23.653 |
| Amortization | 23.077 | 23.087 | 16.345 | ||
| Foreign Exchange Effects | -1.194 | -1.246 | 0.198 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -174.737 | -610.308 | -462.137 | -271.321 | -136.494 |
| Cash From Operating Activities | -249.643 | -453.751 | -374.311 | -288.582 | -216.812 |
| Cash From Operating Activities | 12.423 | 46.727 | 34.642 | 22.867 | 11.402 |
| Amortization | 5.69 | 23.077 | 17.261 | 11.444 | 5.691 |
| Non-Cash Items | 56.881 | 236.74 | 175.039 | 111.744 | 49.828 |
| Changes in Working Capital | -150.111 | -150.54 | -138.895 | -162.759 | -147.394 |
| Cash From Investing Activities | 232.336 | 228.237 | 264.727 | 199.756 | 26.663 |
| Capital Expenditures | -38.655 | -77.34 | -48.095 | -32.161 | -17.397 |
| Other Investing Cash Flow Items, Total | 270.991 | 305.577 | 312.822 | 231.917 | 44.06 |
| Cash From Financing Activities | 29.937 | 125.36 | 60.013 | 41.624 | 26.664 |
| Issuance (Retirement) of Stock, Net | 42.24 | 125.36 | 60.013 | 41.624 | 26.664 |
| Foreign Exchange Effects | 0.92 | -1.194 | -6.893 | -2.809 | -0.353 |
| Net Change in Cash | 13.55 | -101.348 | -56.464 | -50.011 | -163.838 |
| Deferred Taxes | 0.211 | 0.553 | -0.221 | -0.557 | 0.155 |
| Financing Cash Flow Items | -12.303 |
| Investor Name | Investor Type | Percent Outstanding | Shares Held | Shares change | Holdings Date | Turnover Rating |
|---|---|---|---|---|---|---|
| Baker Bros. Advisors LP | Hedge Fund | 23.7372 | 44554162 | -4088 | 2023-06-30 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 7.0615 | 13254362 | 152154 | 2023-06-30 | LOW |
| Pentwater Capital Management LP | Hedge Fund | 5.1303 | 9629500 | 7874500 | 2023-06-30 | HIGH |
| Capital World Investors | Investment Advisor | 4.8383 | 9081409 | -3188031 | 2023-06-30 | LOW |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.4223 | 8300626 | 477794 | 2023-06-30 | LOW |
| Capital International Investors | Investment Advisor | 3.4189 | 6417224 | -810641 | 2023-06-30 | LOW |
| PRIMECAP Management Company | Investment Advisor | 3.2173 | 6038808 | 1144000 | 2023-06-30 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 1.7764 | 3334204 | -20028 | 2023-06-30 | LOW |
| Invesco Capital Management (QQQ Trust) | Investment Advisor | 1.699 | 3188968 | 677696 | 2023-07-31 | LOW |
| Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 1.2007 | 2253733 | -4575730 | 2023-06-30 | LOW |
| Norges Bank Investment Management (NBIM) | Sovereign Wealth Fund | 1.1652 | 2187105 | 473466 | 2022-12-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.0984 | 2061760 | 87737 | 2023-06-30 | LOW |
| Barclays Bank PLC | Investment Advisor | 1.0279 | 1929326 | 1775088 | 2023-06-30 | MED |
| Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 0.9375 | 1759606 | -42300 | 2023-06-30 | LOW |
| Millennium Management LLC | Hedge Fund | 0.8703 | 1633535 | 893994 | 2023-06-30 | HIGH |
| JP Morgan Asset Management | Investment Advisor | 0.8545 | 1603838 | -765853 | 2023-06-30 | LOW |
| Fidelity Management & Research Company LLC | Investment Advisor | 0.701 | 1315820 | -117574 | 2023-06-30 | LOW |
| BlackRock Asset Management Ireland Limited | Investment Advisor | 0.5989 | 1124091 | 250655 | 2023-06-30 | LOW |
| DWS Investments UK Limited | Investment Advisor | 0.4813 | 903451 | 720565 | 2023-06-30 | MED |
| Legal & General Investment Management Ltd. | Investment Advisor/Hedge Fund | 0.4722 | 886400 | 77328 | 2023-06-30 | LOW |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
Seattle Company profile
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.| Industry: | Biotechnology & Medical Research (NEC) |
21823 30Th Drive Se
Suite
BOTHELL
WASHINGTON 98021
US
Income Statement
- Annual
- Quarterly
News
How to Trade The Triple Top
Welcome to Part 5 of our 7-part Power Patterns series. In this series, we'll be equipping you with the skills to trade some of the most indicative price patterns which occur on any timeframe in every market.
14:13, 27 September 2023
Q4 lookahead: US indices starting to show signs of trouble?
US indices start to draw attention as traders focus on the outlook for Q4.
07:20, 27 September 2023
USD/JPY Climbs Towards Key Highs
USDJPY’s powerful long-term uptrend has been reignited after last week’s sharply contrasting policy statements from the Federal Reserve and Bank of Japan.
11:32, 26 September 2023
EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com